Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly

Blood

Volumn 120, Issue 13, 2012, Pages 2768-2769

  Benjamini, Ohad ^a   Jain, Preetesh ^a   Estrov, Zeev ^a   Kantarjian, Hagop M ^a   Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RUXOLITINIB;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; BONE MARROW SUPPRESSION; BONE PAIN; CYTOGENETICS; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATOMEGALY; HUMAN; LETTER; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; NIGHT SWEAT; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; PRURITUS; RASH; SPLENOMEGALY; THROMBOCYTOPENIA; THROMBOCYTOSIS; TREATMENT OUTCOME;

EID: 84866874484     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-07-446849     Document Type: Letter

References (3)

1. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807.
2. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-798.
3. Verstovsek S, Kantarjian HM, Estrov Z, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012;120(6): 1202-1209.